JP2021001196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021001196A5 JP2021001196A5 JP2020155460A JP2020155460A JP2021001196A5 JP 2021001196 A5 JP2021001196 A5 JP 2021001196A5 JP 2020155460 A JP2020155460 A JP 2020155460A JP 2020155460 A JP2020155460 A JP 2020155460A JP 2021001196 A5 JP2021001196 A5 JP 2021001196A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- dosage form
- unit dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 239000003937 drug carrier Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 8
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- 239000008101 lactose Substances 0.000 claims 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000003826 tablet Substances 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229940023488 Pill Drugs 0.000 claims 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 235000001727 glucose Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- WHQDLUUDGYJEGU-MTNJXEIDSA-N Cc1cc(Nc2cc(nccc3)c3c(N[C@H]3C[C@H](CC4)N(CC/C=N\C)[C@H]4C3)n2)n[nH]1 Chemical compound Cc1cc(Nc2cc(nccc3)c3c(N[C@H]3C[C@H](CC4)N(CC/C=N\C)[C@H]4C3)n2)n[nH]1 WHQDLUUDGYJEGU-MTNJXEIDSA-N 0.000 description 1
Claims (22)
- 薬学的組成物であって、
（ａ）式：
（ｂ）デンプン、微結晶性セルロース、ラクトース、リン酸二カルシウム、スクロース、グルコース、マンニトール、ケイ酸およびそれらの組み合わせから選択される薬学的に許容され得るキャリア
を含む、薬学的組成物。 - 前記薬学的に許容され得るキャリアが、微結晶性セルロースを含む、請求項１に記載の薬学的組成物。
- 前記薬学的に許容され得るキャリアが、ラクトースを含む、請求項１に記載の薬学的組成物。
- 前記薬学的に許容され得るキャリアが、微結晶性セルロースおよびラクトースを含む、請求項１に記載の薬学的組成物。
- 前記薬学的組成物が、単位剤形である、請求項１〜４のいずれか１項に記載の薬学的組成物。
- 前記単位剤形が、カプセル剤、錠剤または丸剤である、請求項５に記載の薬学的組成物。
- 前記単位剤形が、錠剤である、請求項５に記載の薬学的組成物。
- 前記単位剤形が、５ｍｇ〜３００ｍｇの前記化合物またはその薬学的に許容され得る塩を含む、請求項５に記載の薬学的組成物。
- 前記化合物が遊離塩基である、請求項１に記載の薬学的組成物。
- 前記化合物が薬学的に許容され得る塩である、請求項１に記載の薬学的組成物。
- 薬学的組成物であって、
（ａ）式：
（ｂ）デンプン、微結晶性セルロース、ラクトース、リン酸二カルシウム、スクロース、グルコース、マンニトール、ケイ酸およびそれらの組み合わせから選択される薬学的に許容され得るキャリア；および
（ｃ）タルク、ステアリン酸カルシウム、ステアリン酸マグネシウム、固体ポリエチレングリコール、ラウリル硫酸ナトリウムおよびそれらの組み合わせから選択される滑沢剤
を含む、薬学的組成物。 - 前記薬学的に許容され得るキャリアが、微結晶性セルロースを含む、請求項１１に記載の薬学的組成物。
- 前記薬学的に許容され得るキャリアが、ラクトースを含む、請求項１１に記載の薬学的組成物。
- 前記薬学的に許容され得るキャリアが、微結晶性セルロースおよびラクトースを含む、請求項１１に記載の薬学的組成物。
- 前記滑沢剤がステアリン酸マグネシウムである、請求項１１に記載の薬学的組成物。
- 前記薬学的に許容され得るキャリアが微結晶性セルロースおよびラクトースを含み、そして前記滑沢剤がステアリン酸マグネシウムである、請求項１１に記載の薬学的組成物。
- 前記薬学的組成物が、単位剤形である、請求項１１〜１６のいずれか１項に記載の薬学的組成物。
- 前記単位剤形が、カプセル剤、錠剤または丸剤である、請求項１７に記載の薬学的組成物。
- 前記単位剤形が、錠剤である、請求項１７に記載の薬学的組成物。
- 前記単位剤形が、５ｍｇ〜３００ｍｇの前記化合物またはその薬学的に許容され得る塩を含む、請求項１７に記載の薬学的組成物。
- 前記化合物が遊離塩基である、請求項１１に記載の薬学的組成物。
- 前記化合物が薬学的に許容され得る塩である、請求項１１に記載の薬学的組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021047526A JP2021098757A (ja) | 2015-05-28 | 2021-03-22 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167694P | 2015-05-28 | 2015-05-28 | |
| US62/167,694 | 2015-05-28 | ||
| US201662312273P | 2016-03-23 | 2016-03-23 | |
| US62/312,273 | 2016-03-23 | ||
| JP2020049467A JP6850922B2 (ja) | 2015-05-28 | 2020-03-19 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020049467A Division JP6850922B2 (ja) | 2015-05-28 | 2020-03-19 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047526A Division JP2021098757A (ja) | 2015-05-28 | 2021-03-22 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021001196A JP2021001196A (ja) | 2021-01-07 |
| JP2021001196A5 true JP2021001196A5 (ja) | 2021-05-06 |
| JP6942853B2 JP6942853B2 (ja) | 2021-09-29 |
Family
ID=56118022
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561259A Active JP6692836B2 (ja) | 2015-05-28 | 2016-05-26 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2020049467A Active JP6850922B2 (ja) | 2015-05-28 | 2020-03-19 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2020155460A Active JP6942853B2 (ja) | 2015-05-28 | 2020-09-16 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2021047526A Withdrawn JP2021098757A (ja) | 2015-05-28 | 2021-03-22 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561259A Active JP6692836B2 (ja) | 2015-05-28 | 2016-05-26 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2020049467A Active JP6850922B2 (ja) | 2015-05-28 | 2020-03-19 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047526A Withdrawn JP2021098757A (ja) | 2015-05-28 | 2021-03-22 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9725470B2 (ja) |
| EP (2) | EP3303348B1 (ja) |
| JP (4) | JP6692836B2 (ja) |
| KR (1) | KR20180011272A (ja) |
| CN (2) | CN107667108B (ja) |
| AU (2) | AU2016267141B2 (ja) |
| BR (1) | BR112017025542A2 (ja) |
| CA (1) | CA2983453A1 (ja) |
| CL (1) | CL2017002994A1 (ja) |
| CO (1) | CO2017012267A2 (ja) |
| CY (1) | CY1122279T1 (ja) |
| DK (1) | DK3303348T3 (ja) |
| EA (1) | EA032953B1 (ja) |
| ES (2) | ES2753159T3 (ja) |
| HK (1) | HK1245771A1 (ja) |
| HU (1) | HUE046130T2 (ja) |
| IL (3) | IL255358B (ja) |
| LT (1) | LT3303348T (ja) |
| ME (1) | ME03610B (ja) |
| MX (2) | MX2020011774A (ja) |
| PH (1) | PH12017502050B1 (ja) |
| PL (1) | PL3303348T3 (ja) |
| PT (1) | PT3303348T (ja) |
| RS (1) | RS59522B1 (ja) |
| SA (1) | SA517390337B1 (ja) |
| SG (1) | SG10201910742VA (ja) |
| SI (1) | SI3303348T1 (ja) |
| TW (2) | TWI746178B (ja) |
| UA (1) | UA121138C2 (ja) |
| WO (1) | WO2016191524A1 (ja) |
| ZA (1) | ZA201707326B (ja) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046130T2 (hu) | 2015-05-28 | 2020-02-28 | Theravance Biopharma R&D Ip Llc | Naftiridin vegyületek mint jak kináz inhibitorok |
| EP3371184A1 (en) | 2015-11-03 | 2018-09-12 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| PT3371185T (pt) | 2015-11-03 | 2020-12-28 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| EP4086256A1 (en) | 2016-12-16 | 2022-11-09 | Janssen Pharmaceutica NV | Small molecule inhibitors of the jak family of kinases |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| DK3672965T3 (da) * | 2017-10-27 | 2022-10-03 | Theravance Biopharma R&D Ip Llc | Pyramidinforbindelse som Jak-kinase-inhibitor |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| WO2020108516A1 (zh) * | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| EP3889152A4 (en) * | 2018-11-30 | 2022-09-07 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATORS, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| JP7470713B2 (ja) * | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| JP7482152B2 (ja) | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115667228A (zh) * | 2020-05-25 | 2023-01-31 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的盐、晶型及其制备方法 |
| WO2022076717A1 (en) * | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solvate forms of a pan-jak inhibitor |
| TW202228689A (zh) | 2020-10-09 | 2022-08-01 | 美商賽若凡斯生物製藥研發智財有限責任公司 | 泛ｊａｋ抑制劑的調配物 |
| US11739103B2 (en) | 2020-10-09 | 2023-08-29 | Theravance Biopharma R&D LP, LLC | Processes for preparing a pan-JAK inhibitor and related intermediate compounds |
| WO2022076714A1 (en) * | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solid forms of a pan-jak inhibitor |
| US20240158392A1 (en) * | 2021-02-01 | 2024-05-16 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| WO2022241188A1 (en) | 2021-05-14 | 2022-11-17 | Theravance Biopharma R&D Ip, Llc | Enantioselective synthesis of aminotropane compound |
| WO2023011359A1 (zh) * | 2021-08-05 | 2023-02-09 | 南京明德新药研发有限公司 | 桥环类化合物及其应用 |
| WO2023102800A1 (en) | 2021-12-09 | 2023-06-15 | Theravance Biopharma R&D Ip, Llc | Synthesis of 5, 7-dichloro-1, 6-naphthyridine |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| KR100947185B1 (ko) | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물 |
| EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| CA2588220A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| EP2142550A1 (en) * | 2007-04-02 | 2010-01-13 | Palau Pharma, S.A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| US20110269740A1 (en) * | 2008-07-02 | 2011-11-03 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| EP2324022A1 (de) | 2008-08-05 | 2011-05-25 | Boehringer Ingelheim International GmbH | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| BRPI0919488A2 (pt) | 2008-09-30 | 2015-12-01 | Astrazeneca Ab | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| CN105367555B (zh) | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| HUE046130T2 (hu) | 2015-05-28 | 2020-02-28 | Theravance Biopharma R&D Ip Llc | Naftiridin vegyületek mint jak kináz inhibitorok |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
-
2016
- 2016-05-26 HU HUE16728495A patent/HUE046130T2/hu unknown
- 2016-05-26 EA EA201792619A patent/EA032953B1/ru unknown
- 2016-05-26 SG SG10201910742VA patent/SG10201910742VA/en unknown
- 2016-05-26 JP JP2017561259A patent/JP6692836B2/ja active Active
- 2016-05-26 UA UAA201712873A patent/UA121138C2/uk unknown
- 2016-05-26 WO PCT/US2016/034243 patent/WO2016191524A1/en active Application Filing
- 2016-05-26 CN CN201680029912.9A patent/CN107667108B/zh active Active
- 2016-05-26 CA CA2983453A patent/CA2983453A1/en not_active Abandoned
- 2016-05-26 AU AU2016267141A patent/AU2016267141B2/en not_active Ceased
- 2016-05-26 EP EP16728495.9A patent/EP3303348B1/en active Active
- 2016-05-26 LT LT16728495T patent/LT3303348T/lt unknown
- 2016-05-26 KR KR1020177037794A patent/KR20180011272A/ko not_active Application Discontinuation
- 2016-05-26 PT PT167284959T patent/PT3303348T/pt unknown
- 2016-05-26 EP EP19182836.7A patent/EP3569604B1/en active Active
- 2016-05-26 PL PL16728495T patent/PL3303348T3/pl unknown
- 2016-05-26 ES ES16728495T patent/ES2753159T3/es active Active
- 2016-05-26 US US15/165,126 patent/US9725470B2/en active Active
- 2016-05-26 RS RS20191390A patent/RS59522B1/sr unknown
- 2016-05-26 DK DK16728495T patent/DK3303348T3/da active
- 2016-05-26 ES ES19182836T patent/ES2924698T3/es active Active
- 2016-05-26 CN CN202010325911.7A patent/CN111362975B/zh active Active
- 2016-05-26 BR BR112017025542-1A patent/BR112017025542A2/pt active Search and Examination
- 2016-05-26 ME MEP-2019-289A patent/ME03610B/me unknown
- 2016-05-26 SI SI201630490T patent/SI3303348T1/sl unknown
- 2016-05-26 MX MX2020011774A patent/MX2020011774A/es unknown
- 2016-05-26 MX MX2017015211A patent/MX2017015211A/es unknown
- 2016-05-27 TW TW109132390A patent/TWI746178B/zh not_active IP Right Cessation
- 2016-05-27 TW TW105116751A patent/TWI704152B/zh not_active IP Right Cessation
-
2017
- 2017-06-23 US US15/631,220 patent/US10072026B2/en active Active
- 2017-10-27 ZA ZA2017/07326A patent/ZA201707326B/en unknown
- 2017-10-31 IL IL255358A patent/IL255358B/en active IP Right Grant
- 2017-11-09 PH PH12017502050A patent/PH12017502050B1/en unknown
- 2017-11-14 SA SA517390337A patent/SA517390337B1/ar unknown
- 2017-11-27 CL CL2017002994A patent/CL2017002994A1/es unknown
- 2017-11-29 CO CONC2017/0012267A patent/CO2017012267A2/es unknown
-
2018
- 2018-04-18 HK HK18105049.0A patent/HK1245771A1/zh unknown
- 2018-08-06 US US16/055,386 patent/US10494382B2/en active Active
-
2019
- 2019-10-11 US US16/599,434 patent/US10947254B2/en active Active
- 2019-11-06 CY CY20191101165T patent/CY1122279T1/el unknown
-
2020
- 2020-01-15 IL IL272057A patent/IL272057B/en active IP Right Grant
- 2020-03-19 JP JP2020049467A patent/JP6850922B2/ja active Active
- 2020-03-27 AU AU2020202181A patent/AU2020202181B2/en not_active Ceased
- 2020-08-12 IL IL276677A patent/IL276677B/en active IP Right Grant
- 2020-09-16 JP JP2020155460A patent/JP6942853B2/ja active Active
-
2021
- 2021-02-10 US US17/248,832 patent/US11780852B2/en active Active
- 2021-03-22 JP JP2021047526A patent/JP2021098757A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021001196A5 (ja) | ||
| JP2006516570A5 (ja) | ||
| JP2011037832A5 (ja) | ||
| JP5557989B2 (ja) | イバンドロネートを含む経口薬理製剤 | |
| JP2016065086A5 (ja) | ||
| JP2015518885A5 (ja) | ||
| JP2008516004A5 (ja) | ||
| JP2015091822A5 (ja) | ||
| JP2018527392A5 (ja) | ||
| JP2013518107A5 (ja) | ||
| JP2016537347A5 (ja) | ||
| JP6154878B2 (ja) | アタザナビルを含む錠剤組成物 | |
| KR20110007602A (ko) | 심장혈관계 질병 예방용 캡슐 | |
| JPWO2023027198A5 (ja) | ||
| JP2007197357A5 (ja) | ||
| JP2015521191A5 (ja) | ||
| JP2020510085A5 (ja) | ||
| JP2021512869A5 (ja) | ||
| HUT74477A (en) | Film coated tablet of paracetamol and domperidone | |
| JP2001526234A5 (ja) | ||
| JP2018118966A5 (ja) | ||
| JP2018503611A5 (ja) | ||
| CN102755336A (zh) | 包含格雷类药物和阿司匹林盐的药物组合物 | |
| JP2019526591A5 (ja) | ||
| JP2017048174A (ja) | 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤 |